Cartesian Therapeutics (RNAC) Tops Q2 EPS by 134c
Tweet
Share
E-mailGet Alerts RNAC Hot Sheet
Join SI Premium – FREE
Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 EPS of $0.46, $1.34 better than the analyst estimate of ($0.88).
For earnings history and earnings-related data on Cartesian Therapeutics (RNAC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Canaccord Starts BillionToOne Inc (BLLN) at Buy
- GoPro (GPRO) call put ratio 2.8 calls to 1 put on 372K contracts amid wide price movement
- Credo Technology Group Holding (CRDO) Tops Q1 EPS by 4c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
